首页> 美国卫生研究院文献>other >Mucosal Tolerance to a Combination of ApoB and HSP60 Peptides Controls Plaque Progression and Stabilizes Vulnerable Plaque in Apobtm2SgyLdlrtm1Her/J Mice
【2h】

Mucosal Tolerance to a Combination of ApoB and HSP60 Peptides Controls Plaque Progression and Stabilizes Vulnerable Plaque in Apobtm2SgyLdlrtm1Her/J Mice

机译:粘膜耐受的apoB和Hsp60肽的组合控制斑块进展和在apobtm2sgyLdlrtm1Her / J小鼠可稳定易损斑块

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Oral tolerance to auto antigens reduces the development of atherosclerosis in mouse models. However, the effect of immune tolerance to multiple self antigenic peptides in plaque progression and stabilization is not known. We studied the protective effect of mucosal tolerance to peptides from apolipoprotein B (ApoB; 661–680) and heat shock protein 60 (HSP60; 153–163), in combination with diet, in the prevention of atherosclerotic lesion progression and plaque stabilization in ApoBtm25gyLDLrtm1Her mice. We found that oral administration of five doses of a combination of ApoB and HSP60 peptides (20 µg/mice/dose) induced tolerance to both the peptides and reduced early plaque development by 39.9% better than the individual peptides (ApoB = 28.7%;HSP60 = 26.8%)(P<0.001). Oral tolerance to combination of peptides along with diet modification arrested plaque progression by 37.6% which was associated with increases in T-regulatory cell and transforming growth factor-β expression in the plaque and peripheral circulation. Reduced macrophage infiltration and tumor necrosis factor-α expression in the plaque was also observed. Tolerance with continued hypercholesterolemia resulted in 60.8% reduction in necrotic core area suggesting plaque stabilization, which was supported by reduction in apoptosis and increased efferocytosis demonstrated by greater expression of receptor tyrosine kinase Mer (MerTK) in the plaque. Tolerance to the two peptides also reduced the expression of matrix metalloproteinase 9, tissue factor, calprotectin, and increased its collagen content. Our study suggests that oral tolerance to ApoB and HSP60 peptide combination induces CD4+ CTLA4+ Tregs and CD4+CD25+Foxp3+ Tregs secreting TGF-β, which inhibit pathogenic T cell response to both peptides thus reducing the development and progression of atherosclerosis and provides evidence for plaque stabilization in ApoBtm25gyLDLrtm1Her mice.
机译:对自身抗原的口服耐受性降低了小鼠模型中动脉粥样硬化的发展。然而,在斑块进展和稳定中对多种自身抗原肽的免疫耐受的作用尚不清楚。我们研究了粘膜耐受对载脂蛋白B(ApoB; 661–680)和热休克蛋白60(HSP60; 153–163)的肽与饮食联合的保护作用,以预防动脉粥样硬化病变的进展和ApoB的斑块稳定 tm25gy LDLr tm1Her 小鼠。我们发现口服五剂ApoB和HSP60肽的组合(20 µg /小鼠/剂量)可诱导对这两种肽的耐受性,并且与单个肽相比,可减少39.9%的早期斑块形成(ApoB = 28.7%; HSP60 = 26.8%)(P <0.001)。多肽组合饮食的口服耐受性和饮食调节使斑块进展停滞了37.6%,这与斑块和外周循环中T调节细胞的增加以及转化生长因子β表达的增加有关。还观察到斑块中巨噬细胞浸润和肿瘤坏死因子-α表达降低。对持续性高胆固醇血症的耐受性导致坏死核心面积减少60.8%,表明斑块稳定,这是由于斑块中受体酪氨酸激酶Mer(MerTK)的表达增加,从而减少了细胞凋亡并增加了胞吐作用。对这两种肽的耐受性也降低了基质金属蛋白酶9,组织因子,钙卫蛋白的表达,并增加了其胶原蛋白含量。我们的研究表明,口服耐受ApoB和HSP60肽组合可诱导CD4 + CTLA4 + Treg和CD4 + CD25 + Foxp3 + 分泌TGF-β的Treg,抑制致病性T细胞对两种肽的反应,从而减少动脉粥样硬化的发生和发展,并为ApoB tm25gy LDLr中的斑块稳定提供证据 tm1Her 小鼠。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号